which could give it an advantage over rival drugs in the class coming through the industry pipeline from the likes of AstraZeneca (AZD4573), Merck & Co (dinaciclib), Tolero (alvocidib) and others.

In a report released yesterday, Luisa Hector from Berenberg Bank maintained a Buy rating on Merck & Company (MRK – Research Report), with a ...

The AstraZeneca PLC ADR AZN advanced 1.42% to $77.60 Friday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index COMP rising 2.61% to ...

AION Labs, the first-of-its-kind venture studio spearheading the adoption of AI technologies and computational science to ...

Berenberg Bank analyst Luisa Hector maintained a Buy rating on Sanofi (SNY – Research Report) yesterday and set a price target of $63.00. The ...

AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to oral anemia drug roxadustat. The two companies' relationship around ...

AstraZeneca and Merck & Co’s partnership to develop ovarian cancer drug Lynparza has got off to a good start after the FDA approved its use in a wider group of women. The drug has been approved ...

FibroGen sells its China unit to AstraZeneca for about $160M, strengthening its cash position and extending its financial runway into 2027. AstraZeneca gains full rights to roxadustat in China ...

Feb 28 (Reuters) - The European Union's health regulator on Friday backed AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab drug Enhertu as a breast cancer treatment ...

Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co ... evaluate its drug with AstraZeneca’s ...